ReQuisite Biomedical was founded to develop intravascular medical device coatings containing a combination of the natural compounds found in red wine – resveratrol and quercetin. The two compounds act in synergy to prevent negative responses to angioplasty treatment that cause re-narrowing of the arteries following a clinical intervention. However, unlike the drugs currently used for drug-coated balloon (DCB) and drug-eluting stent (DES) coatings, these compounds have limited toxicity to vascular cells and have been shown to actively promote positive responses of endothelial progenitor cells, key mediators of the healing response. Resveratrol and quercetin target multiple pathways in disease pathogenesis and should provide a superior healing response compared to products currently on the market and in development.